https://www.selleckchem.com/pr....oducts/as2863619.htm
Requiring a walking aid is a fundamental milestone in multiple sclerosis (MS), represented by an Expanded Disability Status Scale (EDSS) score ≥6.0. In the present study, we assess the effect of ocrelizumab (OCR) on time to EDSS score ≥6.0 in relapsing MS. Time to EDSS score ≥6.0 confirmed for ≥24 and ≥48weeks was assessed over the course of 6.5years (336weeks) in the double-blind period (DBP) and open-label extension (OLE) period of the OPERA I (NCT01247324) and OPERA II (NCT01412333) studies. Time to reach EDSS score ≥6.0 was signif
Like
Comment
Share
